Clinical trials and equitable care pathways are needed to build on early evidence of benefit Substance use disorders (SUDs) are common and burdensome for patients, families, and health systems,12 yet ...

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

Where do indications for GLP-1 receptor agonists (RAs) currently stand? Experts addressed these questions at the French Nutrition Days 2025 in Lyon, France, with a focus on obesity treatment, ...

Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one ...

A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It's a simple premise: What if something as small as a digital nudge could put ...

People struggling with many addictions, ranging from opioids to gambling, are reporting similar experiences in clinics, on social media and around dinner tables.

Kristen Fischer has written for numerous health publications, hospitals, and medical companies, and is a member of the Association of Health Care Journalists. Nick Blackmer is a librarian, ...